The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.
source https://finance.yahoo.com/news/fda-grants-orphan-drug-status-220010432.html?.tsrc=rss
blaineonline.finance.blog 